|
1
|
Fukuoka M, Wu YL, Thongprasert S, et al:
Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
4
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Asano H, Toyooka S, Tokumo M, et al:
Detection of EGFR gene mutation in lung cancer by mutant-enriched
polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoshi K, Takakura H, Mitani Y, et al:
Rapid detection of epidermal growth factor receptor mutations in
lung cancer by the SMart-Amplification Process. Clin Cancer Res.
13:4974–4983. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hall JG, Eis PS, Law SM, et al: Sensitive
detection of DNA polymorphisms by the serial invasive signal
amplification reaction. Proc Natl Acad Sci USA. 97:8272–8277. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naoki K, Soejima K, Okamoto H, et al: The
PCR-invader method (structure-specific 5′ nuclease-based method), a
sensitive method for detecting EGFR gene mutations in lung cancer
specimens; comparison with direct sequencing. Int J Clin Oncol.
16:335–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sasaki H, Endo K, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujimoto T, Konagaya M, Enomoto M, et al:
Novel high-speed real-time PCR method (Hyper-PCR): results from its
application to adenovirus diagnosis. Jpn J infect Dis. 63:31–35.
2010.PubMed/NCBI
|
|
13
|
Asahina H, Yamazaki K, Onodera Y, Kikuchi
E, Shinagawa N, Asano F and Nishimura M: Transbronchial biopsy
using endobronchial ultrasonography with a guide sheath and virtual
bronchoscopic navigation. Chest. 128:1761–1765. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asano F, Matsuno Y, Shinagawa N, Yamazaki
K, Suzuki T, Ishida T and Moriya H: A virtual bronchoscopic
navigation system for pulmonary peripheral lesions. Chest.
130:559–566. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eberhardt R, Anantham D, Ernst A,
Feller-Kopman D and Herth F: Multimodality bronchoscopic diagnosis
of peripheral lung lesions: a randomized controlled trial. Am J
Respir Crit Care Med. 176:36–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eberhardt R, Kahn N, Gompelmann D,
Schumann M, Heussel CP and Herth FJ: LungPoint - a new approach to
peripheral lesions. J Thorac Oncol. 5:1559–1563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fielding DI, Chia C, Nguyen P, Bashirzadeh
F, Hundloe J, Brown IG and Steinke K: Prospective randomised trial
of endobronchial ultrasound-guide sheath versus computed
tomography-guided percutaneous core biopsies for peripheral lung
lesions. Intern Med J. 42:894–900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gildea TR, Mazzone PJ, Karnak D, Meziane M
and Mehta AC: Electromagnetic navigation diagnostic bronchoscopy: a
prospective study. Am J Respir Crit Care Med. 174:982–989. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seijo LM, de Torres JP, Lozano MD,
Bastarrika G, Alcaide AB, Lacunza MM and Zulueta JJ: Diagnostic
yield of electromagnetic navigation bronchoscopy is highly
dependent on the presence of a Bronchus sign on CT imaging: results
from a prospective study. Chest. 138:1316–1321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurimoto N, Miyazawa T, Okimasa S, Maeda
A, Oiwa H, Miyazu Y and Murayama M: Endobronchial ultrasonography
using a guide sheath increases the ability to diagnose peripheral
pulmonary lesions endoscopically. Chest. 126:959–965. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kundel HL and Polansky M: Measurement of
observer agreement. Radiology. 228:303–308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Landis JR and Koch GG: The measurement of
observer agreement for categorical data. Biometrics. 33:159–174.
1977. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vansteenkiste J, De Ruysscher D, Eberhardt
WE, Lim E, Senan S, Felip E and Peters S; ESMO Guidelines Working
Group. Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 24(Suppl 6): vi89–vi98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishida T, Asano F, Yamazaki K, et al:
Virtual bronchoscopic navigation combined with endobronchial
ultrasound to diagnose small peripheral pulmonary lesions: a
randamized trial. Thorax. 66:1072–1077. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi F, Kugawa S, Tateno H, Kokubu F
and Fukuchi K: Analysis of EGFR, KRAS and P53 mutations in lung
cancer using cells in the curette lavage fluid obtained by
bronchoscopy. Lung Cancer. 78:201–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jurado J, Saqi A, Maxfield R, et al: The
efficacy of EBUS-guided transbronchial needle aspiration for
molecular testing in lung adenocarcinoma. Ann Thorac Surg.
96:1196–1202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Santis G, Angell R, Nickless G, Quinn A,
Herbert A, Cane P, Spicer J, Breen R, McLean E and Tobal K:
Screening for EGFR and KRAS mutations in endobronchial ultrasound
derived trans-bronchial needle aspirates in non-small cell lung
cancer using COLD-PCR. PLoS One. 6:e251912011. View Article : Google Scholar
|
|
28
|
Tsai TH, Yang CY, Ho CC, et al: Multi-gene
analyses from waste brushing specimens for patients with peripheral
lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer.
82:420–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lewandowska MA, Jozwicki W, Jochymski C
and Kowalewski J: Application of PCR methods to evaluate EGFR, KRAS
and BRAF mutations in a small number of tumor cells in cytological
material from lung cancer patients. Oncol Rep. 30:1045–1052.
2013.PubMed/NCBI
|
|
30
|
van Eijk R, Licht J, Schrumpf M, et al:
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle
aspirates from non-small-cell lung cancer using allele-specific
qPCR. PLoS One. 6:e177912011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Buttitta F, Felicioni L, Del Grammastro M,
et al: Effective assessment of egfr mutation status in
bronchoalveolar lavage and pleural fluids by next-generation
sequencing. Clin Cancer Res. 19:691–698. 2013. View Article : Google Scholar
|
|
32
|
Pfister DG, Johnson DH, Azzoli CG, et al:
American Society of Clinical Oncology treatment of unresectable
non-small-cell lung cancer guideline: update 2003. J Clin Oncol.
22:330–353. 2004. View Article : Google Scholar
|
|
33
|
Inoue A, Kobayashi K, Usui K, et al:
First-line gefitinib for patients with advanced non-small-cell lung
cancer harboring epidermal growth factor receptor mutations without
indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kudoh S, Kato H, Nishiwaki Y, et al:
Interstitial lung disease in Japanese patients with lung cancer: a
cohort and nested case-control study. Am J Respir Crit Care Med.
177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Watanabe S, Minegishi Y, Yoshizawa H, et
al: Effectiveness of gefitinib against non-small-cell lung cancer
with uncommon EGFR mutations G719X and L861Q. J Thorac Oncol.
9:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cross DA, Ashton SE, Ghiorghiu S, et al:
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Dicov.
4:1046–1061. 2014. View Article : Google Scholar
|
